![Roberto Bellini](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Roberto Bellini
Direktor/Vorstandsmitglied bei
INHIBIKASE THERAPEUTICS, INC.
Vermögen: - $ am 30.06.2026
Profil
Roberto Bellini currently works at BIOTECanada, as Vice Chairman from 2016, Klox Technologies Europe Ltd., as Director, Inhibikase Therapeutics, Inc., as Independent Director from 2025, and Bsquared Capital, Inc., as Managing Partner from 2023.
Mr. Bellini also formerly worked at BELLUS Health, Inc., as President, CEO & Head-Investor Relations from 2010 to 2012, Thallion Pharmaceuticals, Inc., as Independent Director from 2010 to 2013, CellCarta Biosciences, Inc., as Director, Picchio Pharma, Inc., as Executive Vice President, and Prognomix, Inc., as Vice President-Corporate Development.
Mr. Bellini received his undergraduate degree in 2002 from McGill University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Roberto Bellini
| Unternehmen | Position | Beginn |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 14.02.2025 |
BIOTECanada
 BIOTECanada BiotechnologyHealth Technology Engages in research and development in biotechnology | Direktor/Vorstandsmitglied | 04.05.2016 |
FB Dermatology Ltd.
 FB Dermatology Ltd. Pharmaceuticals: OtherHealth Technology Provides skin treatment services | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Roberto Bellini
| Unternehmen | Position | Ende |
|---|---|---|
| BELLUS HEALTH | Vorstandsvorsitzender | 30.06.2023 |
| THALLION PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 24.04.2013 |
Picchio Pharma, Inc.
 Picchio Pharma, Inc. Pharmaceuticals: GenericHealth Technology Engages in acquiring, developing, and commercializing new therapeutic products | Corporate Officer/Principal | 01.12.2009 |
Prognomix, Inc.
 Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Corporate Officer/Principal | - |
CellCarta Biosciences, Inc.
 CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as specialty contract research laboratory | Direktor/Vorstandsmitglied | - |
Ausbildung von Roberto Bellini
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
72
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of refractory chronic disease | Health Technology |
Picchio Pharma, Inc.
Picchio Pharma, Inc. Pharmaceuticals: GenericHealth Technology Engages in acquiring, developing, and commercializing new therapeutic products | Health Technology |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops new pharmaceutical products | Health Technology |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as specialty contract research laboratory | Commercial Services |
BIOTECanada
BIOTECanada BiotechnologyHealth Technology Engages in research and development in biotechnology | Health Technology |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Health Technology |
Inhibikase Therapeutics, Inc.
 Inhibikase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes small-molecule kinase inhibitor therapeutics for neurological diseases | Health Technology |
FB Dermatology Ltd.
FB Dermatology Ltd. Pharmaceuticals: OtherHealth Technology Provides skin treatment services | Health Technology |
Wählen Sie MarketScreener 
